Almost 12 years ago, Dr. Magali Haas, Founder and Former CEO, created what would become Cohen Veterans Bioscience (CVB) with the inspirational vision to advance brain health through cutting-edge research and technology. As we kick off another year, and I start my new role as CEO, I’m humbled and inspired by the incredible momentum CVB has gained. I’m honored to have the opportunity to build on the strong foundation Magali created and to help such a talented team continue to advance brain trauma research that will lead to new diagnostics and therapies to help the millions of people who suffer from the devastating impact of a traumatic brain injury (TBI) or post-traumatic stress disorder (PTSD).
I’m truly excited about the opportunity we have at CVB, and believe we are uniquely positioned to make a real difference for patients. Prior to joining CVB, I spent most of my career in industry working with researchers and developers to bring new healthcare innovations to market intended to fulfill important unmet needs. In this work, I found there are unmet needs that industry is not able to address adequately. So I am very excited to have the opportunity to help CVB’s talented scientists and researchers bridge this gap with a not-for-profit mindset focused on the only end goal that matters—helping people who are suffering from brain trauma.
With CVB’s unique capabilities and community of diverse stakeholders, this will be an exciting year for spurring innovation and advancements. This year, we have many exciting initiatives ahead of us, including:
As I plan for the days, months and years ahead, and we continue to make progress every day, I’m reminded of the goal that drives our research and innovation: to improve the lives of people suffering from PTSD and TBI.
I am grateful for your continued support as we seek to further this mission.
Peter Hoehn, JD
Chief Executive Officer
Cohen Veterans Bioscience
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.